BENDAMUSTINE TREATMENT MAY INDUCE LONG-LASTING COMPLETE HEMATOLOGIC RESPONSE IN RELAPSED/REFRACTORY T-LARGE GRANULAR LYMPHOCYTE LEUKEMIA

被引：0

作者：

Rosamilio, R. ^{[1
]}

Ferrara, I. ^{[1
]}

Annunziata, S. ^{[1
]}

Marino, L. ^{[1
]}

Villani, G. ^{[1
]}

Langella, M. ^{[1
]}

Serio, B. ^{[1
]}

Bianco, R. ^{[1
]}

Ferri, S. ^{[1
]}

Rinaldi, A. ^{[1
]}

Guariglia, R. ^{[1
]}

Selleri, C. ^{[1
]}

机构：

[1] Univ Hosp, Dept Oncohematol, Salerno, Italy

来源：

HAEMATOLOGICA | 2017年 / 102卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PU010

引用

页码：157 / 158

页数：2

共 27 条

[21] CB-103: A novel CSL-NICD inhibitor for the treatment of NOTCH-driven T-cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T-ALL
Medinger, Michael
Junker, Till
Heim, Dominik
Tzankov, Alexandar
Jermann, Philip M.
Bobadilla, Maria
Vigolo, Michele
Lehal, Rajwinder
Vogl, Florian D.
Bauer, Michael
Passweg, Jakob
EJHAEM, 2022, 3 (03): : 1009 - 1012
[22] CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Baird, John H.
Frank, Matthew J.
Craig, Juliana
Patel, Shabnum
Spiegel, Jay Y.
Sahaf, Bita
Younes, Sheren F.
Oak, Jean S.
Natkunam, Yasodha
Ehlinger, Zachary
Reynolds, Warren D.
Arai, Sally
Johnston, Laura J.
Lowsky, Robert
Negrin, Robert S.
Rezvani, Andrew R.
Shiraz, Parveen
Sidana, Surbhi
Weng, Wen-Kai
Schultz, Liora M.
Ramakrishna, Sneha
Davis, Kara L.
Feldman, Steven A.
Mackall, Crystal L.
Miklos, David B.
Muffly, Lori S.
BLOOD, 2020, 136
[23] Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)
Martinelli, Giovanni
Dombret, Herve
Chevallier, Patrice
Ottmann, Oliver G.
Goekbuget, Nicola
Topp, Max S.
Fielding, Adele K.
Sterling, Lulu Ren
Benjamin, Jonathan
Stein, Anthony Selwyn
BLOOD, 2015, 126 (23)
[24] Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia
Lee, Daniel W.
Stetler-Stevenson, Maryalice
Sabatino, Marianna
Yuan, Constance
Fry, Terry J.
Shah, Nirali N.
Delbrook, Cindy
Yates, Bonnie
Zhang, Hua
Zhang, Ling
Tschernia, Nick
Cui, Yongzhi
Feldman, Steven
Kochenderfer, James N.
Rosenberg, Steven A.
Stroncek, David F.
Wayne, Alan S.
Mackall, Crystal L.
BLOOD, 2014, 124 (21)
[25] Effect of long-term ibrutinib treatment on T-cell number and profile in relapsed or refractory chronic lymphocytic leukemia patients: correlation with clinical response and tumor burden up to 4-years follow-up
Palma, Marzia
Heimersson, Kia
Mulder, Tom
Mellstedt, Hakan
Osterborg, Anders
LEUKEMIA & LYMPHOMA, 2020, 61 : 81 - 84
[26] Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study (vol 35, pg 1795, 2017)
Martinelli
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (24) : 2856 - 2856
[27] Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blina-tumomab: Results Froma Phase II, Single-Arm, Multicenter Study (vol 35, pg 1795, 2017)
Martinelli
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) : 2722 - 2722

← 1 2 3 →